US regulator alleges Dr Reddy's breached packaging rules

Tags: Companies
Export-focused drugmaker Dr Reddy's Laboratories Ltd said it was in talks with a US regulator over allegations it violated packaging rules for some prescription drugs sold there between 2008 and 2012.

The allegations by the U.S. government's Consumer Product Safety Commission (CPSC) are the latest in a series of regulatory troubles facing Indian pharmaceutical firms in their biggest export market, the United States.

In a U.S. stock exchange filing this week, Dr Reddy's said the CPSC planned to seek civil penalties against the company for allegedly violating rules intended to prevent children from ingesting harmful substances.

The company said any unfavourable outcome could result in "significant liabilities" and added that it disagreed with the allegations.

Indian drugmakers have suffered a string of drug recalls and manufacturing quality-related issues that have hurt the reputation of the $15 billion-a-year industry as a supplier of cheap generic drugs, and led to increased scrutiny from regulators.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Salman should be punished for what he did and not for who he is

    Salman Khan is a Bollywood phenomenon. On the professional front, he can do no wrong.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Simon J Evenett

Trade policy: more heat than light?

After several years in the doldrums, trade policy is back. ...

Zehra Naqvi

Happy people are better workers

We know that the state of mind we are in ...

Dharmendra Khandal

Tales from the dry, deciduous forest of Kuno

Kuno is an incredibly dry deciduous (dhonk) tree forest of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture